Longevity Biotech
Samuel Gellman is a Co-Founder and CSO at Longevity Biotech. He is also a Professor of Chemistry at University of Wisconsin-Madison.
Samuel earned his PhD at Harvard.
This person is not in any offices
Longevity Biotech
Longevity Biotech is developing a new class of therapeutic candidates called Hybridtides. Their focus is on delivering clinically transformative products that tackle the most challenging aspects of medicine today.